Localized gastrointestinal stromal tumors (GIST): an exploratory open-label, multicenter, single-arm phase II study to evaluate the efficacy of 2 years of adjuvant nilotinib treatment following at least 1 year of adjuvant imatinib mesylate
Latest Information Update: 04 Apr 2022
Price :
$35 *
At a glance
- Drugs Nilotinib (Primary) ; Imatinib
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- 02 Apr 2022 Status changed from recruiting to completed.
- 08 Jun 2012 New trial record